Erlotinib and dacomitinib are inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and are used to treat non-small cell lung cancer, pancreatic cancer, and several other cancer types. This evidence concerns the gene EGFR and non-small cell lung carcinoma.